Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2
Abstract
:1. Introduction
2. Results
2.1. Patient Demographics
2.2. Referring Diagnoses and OCTA Findings
2.3. Management of Eyes with SRNV
2.4. Treatment of Co-Existing Macular Holes
2.5. OCTA Quantitative Parameters
3. Discussion
4. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Charbel Issa, P.; Heeren, T.F.C.; Kupitz, E.H.; Holz, F.G.; Berendschot, T.T.J.M. Very early disease manifestations of macular telangiectasia type 2. Retina 2016, 36, 524–534. [Google Scholar] [CrossRef] [PubMed]
- Issa, P.C.; Gillies, M.C.; Chew, E.Y.; Bird, A.C.; Heeren, T.F.C.; Peto, T.; Holz, F.G.; Scholl, H.P.N. Macular Telangiectasia Type 2. Prog. Retin. Eye Res. 2013, 34, 49–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gass, J.D.M.; Blodi, B.A. Idiopathic Juxtafoveolar Retinal Telangiectasis: Update of Classification and Follow-up Study. Ophthalmology 1993, 100, 1536–1546. [Google Scholar] [CrossRef]
- Gillies, M.C.; Mehta, H.; Bird, A.C. Macular Telangiectasia Type 2 without Clinically Detectable Vasculopathy. JAMA Ophthalmol. 2015, 133, 951–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Powner, M.B.; Gillies, M.C.; Tretiach, M.; Scott, A.; Guymer, R.H.; Hageman, G.S.; Fruttiger, M. Perifoveal Müller Cell Depletion in a Case of Macular Telangiectasia Type 2. Ophthalmology 2010, 117, 2407–2416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heeren, T.F.C.; Holz, F.G.; Issa, P.C. First symptoms and their age of onset in macular telangiectasia type 2. Retina 2014, 34, 916–919. [Google Scholar] [CrossRef]
- Aung, K.Z.; Wickremasinghe, S.S.; Makeyeva, G.; Robman, L.; Guymer, R.H. The prevalence estimates of macular telangiectasia type 2: The Melbourne Collaborative Cohort Study. Retina 2010, 30, 473–478. [Google Scholar] [CrossRef]
- Klein, R.; Blodi, B.A.; Meuer, S.M.; Myers, C.E.; Chew, E.Y.; Klein, B.E.K. The Prevalence of Macular Telangiectasia Type 2 (MT2) in the Beaver Dam Eye Study. Am. J. Ophthalmol. 2010, 150, 55–62.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toto, L.; Di Antonio, L.; Mastropasqua, R.; Mattei, P.A.; Carpineto, P.; Borrelli, E.; Rispoli, M.; Lumbroso, B.; Mastropasqua, L. Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography. Investig. Ophthalmol. Vis. Sci. 2016, 57, OCT268–OCT276. [Google Scholar] [CrossRef] [Green Version]
- Pauleikhoff, L.; Heeren, T.F.C.; Gliem, M.; Lim, E.; Pauleikhoff, D.; Holz, F.G.; Clemons, T.; Balaskas, K.; Egan, C.A.; Issa, P.C. Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9. Am. J. Ophthalmol. 2021, 228, 27–34. [Google Scholar] [CrossRef]
- Bottoni, F.; Eandi, C.M.; Pedenovi, S.; Staurenghi, G. Integrated clinical evaluation of Type 2A idiopathic juxtafoveolar retinal telangiectasis. Retina 2010, 30, 317–326. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.H.; Chung, Y.-R.; Oh, J.; Kim, S.-W.; Lee, C.S.; Yun, C.; Lee, B.; Ahn, S.M.; Choi, E.Y.; Jang, S.; et al. Optical Coherence Tomographic Features of Macular Telangiectasia Type 2: Korean Macular Telangiectasia Type 2 Study—Report No. 1. Sci. Rep. 2020, 10, 16594. [Google Scholar] [CrossRef] [PubMed]
- Wu, L. Multimodality Imaging in Macular Telangiectasia 2: A Clue to Its Pathogenesis. Indian J. Ophthalmol. 2015, 63, 394–398. [Google Scholar] [CrossRef]
- Greig, E.C.; Duker, J.S.; Waheed, N.K. A Practical Guide to Optical Coherence Tomography Angiography Interpretation. Int. J. Retina Vitr. 2020, 6, 55. [Google Scholar] [CrossRef] [PubMed]
- Nalcı, H.; Şermet, F.; Demirel, S.; Özmert, E. Optic Coherence Angiography Findings in Type-2 Macular Telangiectasia. Turk. J. Ophthalmol. 2017, 47, 279–284. [Google Scholar] [CrossRef]
- Spaide, R.F.; Klancnik, J.M., Jr.; Cooney, M.J. Retinal Vascular Layers in Macular Telangiectasia Type 2 Imaged by Optical Coherence Tomographic Angiography. JAMA Ophthalmol. 2015, 133, 66–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tzaridis, S.; Heeren, T.; Mai, C.; Thiele, S.; Holz, F.G.; Charbel Issa, P.; Herrmann, P. Right-Angled Vessels in Macular Telangiectasia Type 2. Br. J. Ophthalmol. 2021, 105, 1289–1296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, Y.G.; Park, Y.-H. Quantitative Analysis of Retinal Microvascular Changes in Macular Telangiectasia Type 2 Using Optical Coherence Tomography Angiography. PLoS ONE 2020, 15, e0232255. [Google Scholar] [CrossRef]
- Dogan, B.; Erol, M.K.; Akidan, M.; Suren, E.; Akar, Y. Retinal Vascular Density Evaluated by Optical Coherence Tomography Angiography in Macular Telangiectasia Type 2. Int. Ophthalmol. 2019, 39, 2245–2256. [Google Scholar] [CrossRef]
- Chidambara, L.; Gadde, S.G.K.; Yadav, N.K.; Jayadev, C.; Bhanushali, D.; Appaji, A.M.; Akkali, M.; Khurana, A.; Shetty, R. Characteristics and Quantification of Vascular Changes in Macular Telangiectasia Type 2 on Optical Coherence Tomography Angiography. Br. J. Ophthalmol. 2016, 100, 1482–1488. [Google Scholar] [CrossRef]
- Runkle, A.P.; Kaiser, P.K.; Srivastava, S.K.; Schachat, A.P.; Reese, J.L.; Ehlers, J.P. OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study. Investig. Ophthalmol. Vis. Sci. 2017, 58, 3683–3689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peto, T.; Heeren, T.F.C.; Clemons, T.E.; Sallo, F.B.; Leung, I.; Chew, E.Y.; Bird, A.C. Correlation of clinical and structural progression with visual acuity loss in macular telangiectasia type 2: MacTel Project Report No. 6–The MacTel Research Group. Retina 2018, 38, S8. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.L.; Levinson, D.H.; Levine, J.P.; Mian, U.; Tsui, I. Optical Coherence Tomography Findings in Idiopathic Macular Holes. J. Ophthalmol. 2011, 2011, 928205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Charbel Issa, P.; Scholl, H.P.N.; Gaudric, A.; Massin, P.; Kreiger, A.E.; Schwartz, S.; Holz, F.G. Macular Full-Thickness and Lamellar Holes in Association with Type 2 Idiopathic Macular Telangiectasia. Eye 2009, 23, 435–441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miller, A.G.; Chandra, R.; Pophal, C.; Schartman, J.P.; Hornik, J.H.; Miller, D.G. Efficacy of Macular Hole Surgery in Patients with Idiopathic Macular Telangiectasia Type 2. Ophthalmol. Retina 2020, 4, 494–497. [Google Scholar] [CrossRef]
- Karth, P.A.; Raja, S.C.; Brown, D.M.; Kim, J.E. Outcomes of macular hole surgeries for macular telangiectasia type 2. Retina 2014, 34, 907–915. [Google Scholar] [CrossRef]
- Ahmad, K.T.; Chacko, J.; Sallam, A.B.; Warner, D.B.; Uwaydat, S.H. Surgical Outcomes in Macular Telangiectasia Type 2-Related Macular Holes: A Report on Four Patients. Case Rep. Ophthalmol. Med. 2020, 2020, 8884638. [Google Scholar] [CrossRef]
- Nishiyama, S.; Iwase, T. Two Years Outcomes of Treating Full-Thickness Macula Hole Associated with Idiopathic Macular Telangiectasia Type 2 by Internal Limiting Membrane Inverted Flap Technique. Medicine 2021, 100, e27078. [Google Scholar] [CrossRef]
- Sokol, J.T.; Schechet, S.A.; Komati, R.; Eliott, D.; Vavvas, D.G.; Kaplan, R.I.; Ittiara, S.T.; Farooq, A.V.; Sheth, V.S.; MacCumber, M.W.; et al. Macular Hole Closure with Medical Treatment. Ophthalmol. Retina 2021, 5, 711–713. [Google Scholar] [CrossRef]
- Chandra, V.; Merani, R.; Hunyor, A.P.; Gillies, M. Spontaneous Closure of a Macular Hole in Macular Telangiectasia Type 2. J. Vitreoretin. Dis. 2021, 5, 275–280. [Google Scholar] [CrossRef]
- Nalci, H.; Batioglu, F.; Demirel, S.; Özmert, E. Spontaneous closure of macular hole in a patient with macular telangiectasia type 2. Retin. Cases Brief Rep. 2021, 15, 369–372. [Google Scholar] [CrossRef] [PubMed]
- Balaratnasingam, C.; Dansingani, K.; Dhrami-Gavazi, E.; Yu, S.; Freund, K.B.; Yannuzzi, L.A. Documentation of Spontaneous Macular Hole Closure in Macular Telangiectasia Type 2 Using Multimodal Imaging. Ophthalmic Surg. Lasers Imaging Retina 2015, 46, 883–886. [Google Scholar] [CrossRef] [PubMed]
- Chew, E.Y.; Clemons, T.E.; Peto, T.; Sallo, F.B.; Ingerman, A.; Tao, W.; Singerman, L.; Schwartz, S.D.; Peachey, N.S.; Bird, A.C. Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel): Results from a Phase I Safety Trial. Am. J. Ophthalmol. 2015, 159, 659–666.e1. [Google Scholar] [CrossRef] [Green Version]
- Chew, E.Y.; Clemons, T.E.; Jaffe, G.J.; Johnson, C.A.; Farsiu, S.; Lad, E.M.; Guymer, R.; Rosenfeld, P.; Hubschman, J.-P.; Constable, I.; et al. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology 2019, 126, 540–549. [Google Scholar] [CrossRef]
- Tzaridis, S.; Hess, K.; Friedlander, M.; Holz, F.G. Optical Coherence Tomography-Angiography for Monitoring Neovascularisations in Macular Telangiectasia Type 2. Br. J. Ophthalmol. 2021, 105, 735–740. [Google Scholar] [CrossRef]
- Toygar, O.; Guess, M.G.; Youssef, D.S.; Miller, D.M. Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina 2016, 36, 2150–2157. [Google Scholar] [CrossRef] [PubMed]
- Sen, S.; Rajan, R.P.; Damodaran, S.; Arumugam, K.K.; Kannan, N.B.; Ramasamy, K. Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Monotherapy in Proliferative Type 2 Macular Telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2021, 259, 1135–1143. [Google Scholar] [CrossRef]
- Kim, E.J.; Lin, W.V.; Rodriguez, S.M.; Chen, A.; Loya, A.; Weng, C.Y. Treatment of Diabetic Macular Edema. Curr. Diab. Rep. 2019, 19, 68. [Google Scholar] [CrossRef]
- Postsurgical Cystoid Macular Edema-Abstract-Macular Edema-Karger Publishers. Available online: https://www.karger.com/Article/Abstract/455280 (accessed on 7 December 2021).
Patient | Demographics | Duration of Follow-Up (Years) | Eye | Referral Diagnosis | Baseline BCVA (Snellen) | Final BCVA (Snellen) | Evidence of SRNV on OCTA | Treatment |
---|---|---|---|---|---|---|---|---|
A | 66-year-old Caucasian Female | 0.70 | OD | Unconfirmed MacTel | 20/40 | 20/40 | Yes | Observation |
OS | Unconfirmed MacTel | 20/25 | 20/25 | No | Observation | |||
B | 74-year-old Caucasian Female | 0.61 | OD | Macular hole | 20/60 | 20/40 | No | Drop therapy for macular hole closure |
OS | Macular hole | 20/30 | 20/30 | No | Drop therapy for macular hole closure | |||
C | 63-year-old African American Female | 0.46 | OD | Unconfirmed MacTel | 20/20 | 20/20 | Yes | Observation |
OS | Unconfirmed MacTel | 20/20 | 20/25 | Yes | Observation | |||
D | 70-year-old Caucasian Male | 2.43 | OD | Macular hole | 20/60 | 20/40 | Yes | Anti-VEGF injections at 1 and 5 months |
OS | Macular hole | 20/30 | 20/30 | Yes | Observation | |||
E | 54-year-old Caucasian Male | 3.83 | OD | Macular hole | 20/125 | 20/60 | Yes | Anti-VEGF injections at baseline, 1, and 3 months |
OS | Lamellar hole | 20/25 | 20/25 | No | Observation | |||
F | 74-year-old Caucasian Female | 1.77 | OD | VMT, macular hole | 20/70 | 20/80 | No | Observation |
OS | VMT, lamellar hole | 20/80 | 20/70 | Yes | Observation | |||
G | 64-year-old Caucasian Male | 0.32 | OS | Post-operative CME, cystic lamellar hole | 20/100 | 20/50 | No | Observation |
H | 58-year-old African American Female | 2.96 | OD | DME | 20/30 | 20/25 | No | Observation |
OS | DME | 20/40 | 20/25 | No | Observation |
Baseline (SD) | Final (SD) | p-Value a | |
---|---|---|---|
BCVA (LogMAR) | 0.33 (0.25) | 0.25 (0.18) | 0.035 * |
Signal Strength | 66.9 (6.26) | 67.05 (5.34) | 0.94 |
EZ loss (mm) | 0.90 (0.48) | 0.82 (0.68) | 0.70 |
Superficial Parafoveal VD (%) | 47.47 (2.12) | 46.41 (3.17) | 0.26 |
Deep Parafoveal VD (%) | 54.71 (3.79) | 54.93 (4.15) | 0.86 |
FAZ Area (mm2) | 0.38 (0.14) | 0.37 (0.17) | 0.75 |
FAZ AI | 1.16 (0.05) | 1.14 (0.05) | 0.4 |
FD-300 (%) | 51.41 (5.29) | 49.05 (8.27) | 0.12 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moir, J.; Amin, S.V.; Khanna, S.; Komati, R.; Shaw, L.T.; Dao, D.; Hariprasad, S.M.; Skondra, D. Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2. Int. J. Mol. Sci. 2022, 23, 7849. https://doi.org/10.3390/ijms23147849
Moir J, Amin SV, Khanna S, Komati R, Shaw LT, Dao D, Hariprasad SM, Skondra D. Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2. International Journal of Molecular Sciences. 2022; 23(14):7849. https://doi.org/10.3390/ijms23147849
Chicago/Turabian StyleMoir, John, Shivam V. Amin, Saira Khanna, Rahul Komati, Lincoln T. Shaw, David Dao, Seenu M. Hariprasad, and Dimitra Skondra. 2022. "Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2" International Journal of Molecular Sciences 23, no. 14: 7849. https://doi.org/10.3390/ijms23147849